News archive

Filter by: Reset

March 2022

- 15 March 2022
- JSR Life Sciences
JSR Life Sciences’ Amsphere A3 Integrated into the Commercial Manufacturing of FDA-Approved Antibody Therapy

JSR Life Sciences announced that its lead product, Amsphere™ A3 has been incorporated for the first time into the commercial manufacturing of an FDA-approved treatment
- 14 March 2022
JSR enters into Contract R&D Agreement with AMED for Development of Basic Technologies for Next-Generation Therapeuti...

This project will conduct R&D aimed at the establishment and practical application of a wide range of fundamental technologies related to intestinal microbiome drug discovery for the creation of in...
- 10 March 2022
- KBI Biopharma
Oragenics Engages KBI Biopharma to Support Development of the Intranasal COVID-19 Vaccine Candidate NT-CoV2-1

KBI to Produce Material for Use in Upcoming Phase 2 Clinical Trial of Oragenics’ Intranasal Vaccine Candidate
- 3 March 2022
- MBL
MBL Donated 20,000 SARS-CoV-2 Antigen Test Kits to Ina City, Nagano Prefecture in Japan

MBL donated 20,000 their SARS-CoV-2 antigen test kits "GLINE-2019-nCoV Ag kit" to Ina City, Nagano Prefecture, where their research and production facilities are located

- 11 February 2022
- MBL
Acquisition of Manufacturing and Marketing Approval for SARS-CoV-2 Antigen Rapid Test and Release on 14th February

With a simple operation, the presence or absence of the SARS-CoV-2 antigen can be determined in 15 minutes

- 26 January 2022
- MBL
MBL Announces IVD Product Certification for MEBGEN AZF Deletion Kit for the Japanese Market

The kit is designed to detect the presence or absence of AZF deletion and the type of AZF deletion in Japanese men prior to microdissection testicular sperm extraction for male infertility
- 19 January 2022
- KBI Biopharma
Selexis and Inotrem Enter Service Agreement to Advance Inotrem’s Chronic Inflammatory Disease Program

Selexis and Inotrem have signed a service agreement to develop the cell line for Inotrem’s antibody-based candidate to address chronic inflammations
- 18 January 2022
- JSR Life Sciences
Aqualung Therapeutics Corp., an Immunotherapeutics Biotech Company, Closes a $2.5M Convertible Note Raise With a Comm...

Aqualung Therapeutics has closed a $2.5M convertible note fund raise led by a $1.5M investment from JSR Life Sciences, LLC
- 12 January 2022
- KBI Biopharma
Hemogenyx Pharmaceuticals and Selexis SA Will Advance Hemogenyx’s Acute Myeloid Leukemia (AML) CDX Bispecific Antibod...

Hemogenyx Pharmaceuticals will leverage Selexis’ SUREtechnology Platform™ of protein expression technologies and modular workflows

3 of 3